Paper41276263
Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.
Bergman H and 12 others. Cochrane Database Syst Rev, 2025. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Papers, record 41276263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41276263
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Papillomavirus Vaccines | Major topic |
| Uterine Cervical Neoplasms | Major topic |
| Papillomavirus Infections | Major topic |
| Humans | |
| Female | |
| Randomized Controlled Trials as Topic | |
| Male | |
| Adult | |
| Adolescent | |
| Middle Aged | |
| Young Adult | |
| Bias | |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | |
| Child | |
| Human Papillomavirus Viruses |
Source PubMed
Trials53
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00090285 | An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00122681 | Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00196924 | Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00290277 | Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00294047 | Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00306241 | A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00309166 | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males. | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00316693 | Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00344032 | Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00345878 | Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00365378 | Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00365716 | Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00423046 | Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00426361 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00481767 | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00485732 | A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00496626 | An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00501137 | A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00520598 | Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00534638 | Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents | Derived from the trial | ClinicalTrials.gov |
References293
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34780705 | Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. | Lancet Infect Dis | 2022 | https://conductscience.org/library/papers/34780705 | PubMed |
| 2 | 20413076 | Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. | J Adolesc Health | 2010 | https://conductscience.org/library/papers/20413076 | PubMed |
| 3 | 29424799 | Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial. | Pediatr Infect Dis J | 2018 | https://conductscience.org/library/papers/29424799 | PubMed |
| 4 | 38043220 | British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: An update on recommendations for practice 2023. | Eur J Obstet Gynecol Reprod Biol | 2024 | https://conductscience.org/library/papers/38043220 | PubMed |
| 5 | 30249615 | Challenges of independent assessment of potential harms of HPV vaccines. | BMJ | 2018 | https://conductscience.org/library/papers/30249615 | PubMed |
| 6 | 31742639 | Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015. | J Natl Cancer Inst | 2020 | https://conductscience.org/library/papers/31742639 | PubMed |
| 7 | 31755549 | Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. | Cochrane Database Syst Rev | 2019 | https://conductscience.org/library/papers/31755549 | PubMed |
| 8 | 31551002 | Safety and efficacy of human papillomavirus vaccination for people living with HIV: A systematic review and meta-analysis. | Int J STD AIDS | 2019 | https://conductscience.org/library/papers/31551002 | PubMed |
| 9 | 27697753 | Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. | BMJ | 2016 | https://conductscience.org/library/papers/27697753 | PubMed |
| 10 | 23770335 | A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years. | Vaccine | 2013 | https://conductscience.org/library/papers/23770335 | PubMed |
| 11 | 20139221 | Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. | J Natl Cancer Inst | 2010 | https://conductscience.org/library/papers/20139221 | PubMed |
| 12 | 35358015 | The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age. | Hum Vaccin Immunother | 2022 | https://conductscience.org/library/papers/35358015 | PubMed |
| 13 | 21629249 | End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. | Br J Cancer | 2011 | https://conductscience.org/library/papers/21629249 | PubMed |
| 14 | 24055350 | Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. | Vaccine | 2014 | https://conductscience.org/library/papers/24055350 | PubMed |
| 15 | 26467666 | Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. | J Natl Cancer Inst | 2016 | https://conductscience.org/library/papers/26467666 | PubMed |
| 16 | 38049621 | Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. | Nat Med | 2023 | https://conductscience.org/library/papers/38049621 | PubMed |
| 17 | 36855835 | Attitudes to reducing cervical screening frequency among UK women: A qualitative analysis. | Psychooncology | 2023 | https://conductscience.org/library/papers/36855835 | PubMed |
| 18 | 21734063 | Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. | Clin Vaccine Immunol | 2011 | https://conductscience.org/library/papers/21734063 | PubMed |
| 19 | 31829767 | Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years. | Hum Vaccin Immunother | 2020 | https://conductscience.org/library/papers/31829767 | PubMed |
| 20 | 27354258 | A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. | Vaccine | 2016 | https://conductscience.org/library/papers/27354258 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42724481 | Survival outcomes of postoperative radiotherapy and chemotherapy in early-stage cervical cancer: a Surveillance, Epidemiology, and End Results database-based stratified analysis. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724481 | PubMed |
| 42698614 | Willingness to receive cross-border human papillomavirus vaccination among Chinese male university students: a cross-sectional study with statistical indirect-association analysis. | Front Public Health | 2026 | https://conductscience.org/library/papers/42698614 | PubMed |
| 42506658 | Human Papillomavirus Vaccine Intent and Associated Factors Among the Unvaccinated University Freshmen in the Largest University Town in China. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42506658 | PubMed |
| 42453778 | Real-world Impact of HPV Vaccination on CIN2+ Reduction: A Meta-analysis of Observational Studies Assessing Variation by Age, Coverage, and Vaccine Type. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/42453778 | PubMed |
| 42449659 | HPV-Related Disease: Gynecologists' Leadership in Patient-Centered Multidisciplinary Care. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42449659 | PubMed |
| 42415479 | Moving Beyond the Female-Only Paradigm: Arguments for Accelerating the Global Gender-Neutral Human Papillomavirus Vaccination. | Cancer Control | 2026 | https://conductscience.org/library/papers/42415479 | PubMed |
| 42409728 | The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses. | Hum Vaccin Immunother | 2026 | https://conductscience.org/library/papers/42409728 | PubMed |
| 42334459 | Understanding the roots of hesitancy to unlock the game-changing impact of HPV vaccination: Insights from a global qualitative evidence synthesis. | Hum Vaccin Immunother | 2026 | https://conductscience.org/library/papers/42334459 | PubMed |
| 41877638 | Correcting what cannot be corrected: rethinking publication bias analysis methods in clinical meta-analyses. | Korean J Anesthesiol | 2026 | https://conductscience.org/library/papers/41877638 | PubMed |
| 41724739 | HPV vaccination willingness and its determinants among male university students post-approval of male-specific HPV vaccines in China: a large-scale cross-sectional study. | BMC Public Health | 2026 | https://conductscience.org/library/papers/41724739 | PubMed |
| 41276264 | Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination. | Cochrane Database Syst Rev | 2025 | https://conductscience.org/library/papers/41276264 | PubMed |
| 41276263 | Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. | Cochrane Database Syst Rev | 2025 | https://conductscience.org/library/papers/41276263 | PubMed |
| 40900298 | FIGO position statement on the effectiveness and safety of the HPV vaccine. | Int J Gynaecol Obstet | 2025 | https://conductscience.org/library/papers/40900298 | PubMed |
| 40687764 | Factors associated with the intention to vaccinate and price sensitivity to the human papillomavirus (HPV) vaccine among Chinese male medical college students: a cross-sectional survey. | PeerJ | 2025 | https://conductscience.org/library/papers/40687764 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN | CHEMBL4297973 | Derived from the trial | 3 | https://conductscience.org/library/drugs/CHEMBL4297973 | ChEMBL |
| HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES | CHEMBL6068359 | Derived from the trial | 4 | https://conductscience.org/library/drugs/CHEMBL6068359 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41276263
GET https://conductscience.org/api/papers/v1/41276263/trials?page=2